Skip to main content

Table 2 Unadjusted HR estimates of the treatment effect for DFS and OS according to Prosigna ROR scores and subtype

From: The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer

 

DFS

OS

HR

(95% CI)

Pinteraction

HR

(95% CI)

P interaction

ROR score

  

0.47

  

0.24

 Low tertile

0.79

(0.42–1.47)

 

1.09

(0.70–1.71)

 

 Intermediate tertile

0.49

(0.30–0.79)

 

0.75

(0.50–1.13)

 

 High tertile

0.64

(0.42–0.98)

 

0.66

(0.46–0.96)

 

Subtype

  

0.003

  

0.04

 Luminal A

0.64

(0.36–1.14)

 

0.96

(0.62–1.48)

 

 Luminal B

0.47

(0.28–0.77)

 

0.51

(0.33–0.77)

 

 Basal-like

0.19

(0.09–0.40)

 

0.52

(0.24–1.12)

 

 Her2-enriched

1.04

(0.62–1.75)

 

1.10

(0.71–1.71)

 
  1. DFS disease-free survival, OS overall survival, HR hazard ratio, ROR risk of recurrence, 95% CI 95% confidence interval, Pinteraction P derived from a Wald test for heterogeneity, Her2 human epidermal growth factor receptor 2
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us